Symbiotec Pharmalab IPO

Symbiotec Pharmalab Limited is a research and development-driven pharmaceutical and biotechnology company with capabilities across organic chemistry, biotechnology and complex injectables. It held a global leadership position in corticosteroid and steroidal-hormone APIs in volume terms in Fiscal 2025, with market shares of 36.2% and 44.2%, respectively. It was the only Indian and global company present across the top 10 corticosteroid and steroidal-hormone APIs during the period. With over 30 years of experience, the company has evolved from a lab-scale steroidal-hormone API manufacturer into an industrial-scale, backward-integrated platform with approvals from the USFDA, EU-GMP and other global regulators. It also operates as a CDMO for specialty pharmaceutical and nutraceutical companies globally. As of June 30, 2025, it had two operational API facilities with chemical synthesis capacity of 584.67 MT and fermentation capacity of 300 KL. Newly commissioned facilities increased fermentation capacity to 700 KL and added complex injectable capacity of 20 million vials annually. The company is also expanding its biologics capacity in Ujjain.